Brentuximab vedotin: clinical updates and practical guidance

Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jun Ho, Kim, Seok Jin, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762734/
https://www.ncbi.nlm.nih.gov/pubmed/29333400
http://dx.doi.org/10.5045/br.2017.52.4.243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762734/
https://www.ncbi.nlm.nih.gov/pubmed/29333400
http://dx.doi.org/10.5045/br.2017.52.4.243

Ejemplares similares